TABLE 2.

Resveratrol clinical trials for cancer.

Condition	Phase	Subjects	Dose	Outcome	References
Cancer prevention	I	40	500, 1,000, 2,500, 5,000 mg/day 29 day	RSV safe, but higher doses had GI side effects; RSV treatment caused decrease in IGF-I and IGFBP-3 levels	Brown et al., 2010
CRC	I	20	5,000, 1,000 mg/day 8 day	RSV treatment reduced tumor cell proliferation by 5%	Patel et al., 2010
Cancer prevention	I	42	1,000 mg/day	RSV affected enzymes involved in carcinogen activation and detoxification (CYP3A4, CYP2D6, CYP2C9)	Chow et al., 2010
Multiple Myeloma	II	24	5,000 mg	Terminated early-severe renal side effects	Popat et al., 2013